Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HUM stock price vs LAD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LAD's multiple
Needs Annual EPS, LAD P/E.
Implied fair value · at HUM's multiple
Needs Annual EPS, HUM P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HUMANA INC · implied price per share
Reporting currency could not be verified.
LITHIA MOTORS INC · implied price per share
Reporting currency could not be verified.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
HUM · not enough data.
LAD · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
UNITEDHEALTH GROUP INC
HUM vs UNH
Elevance Health, Inc.
HUM vs ELV
CVS HEALTH Corp
HUM vs CVS
Cigna Group
HUM vs CI
CENTENE CORP
HUM vs CNC
Oscar Health, Inc.
HUM vs OSCR
PENSKE AUTOMOTIVE GROUP, INC.
HUM vs PAG
AUTONATION, INC.
HUM vs AN
GROUP 1 AUTOMOTIVE INC
HUM vs GPI
ASBURY AUTOMOTIVE GROUP INC
HUM vs ABG
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HUM’s superior growth, ROIC, and strong distress profile will persist and re-rate the stock above its current earnings multiple, then hold or accumulate selectively because the current price already embeds a steep valuation premium versus LAD despite HUM’s better growth profile.
On the provided P/E valuation, HUM’s current price of $404.34 versus an implied price of $100.71 suggests 75.1% downside. The discount/premium signal is directionally bearish on valuation alone, but LAD set is not fully apples-to-apples because HUM trades at a much higher P/E than LAD while also showing stronger growth and ROIC.
Supporting Metrics
